CN1935262B - 红色诺卡氏菌细胞壁骨架在制备抗人乳头瘤病毒药物的用途 - Google Patents
红色诺卡氏菌细胞壁骨架在制备抗人乳头瘤病毒药物的用途 Download PDFInfo
- Publication number
- CN1935262B CN1935262B CN2005101055337A CN200510105533A CN1935262B CN 1935262 B CN1935262 B CN 1935262B CN 2005101055337 A CN2005101055337 A CN 2005101055337A CN 200510105533 A CN200510105533 A CN 200510105533A CN 1935262 B CN1935262 B CN 1935262B
- Authority
- CN
- China
- Prior art keywords
- hpv
- medicine
- virus
- treatment
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 241000187654 Nocardia Species 0.000 title claims description 14
- 241000701806 Human papillomavirus Species 0.000 title abstract description 12
- 210000004292 cytoskeleton Anatomy 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 7
- 229940040145 liniment Drugs 0.000 claims description 5
- 239000000865 liniment Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 108010039939 Cell Wall Skeleton Proteins 0.000 claims description 3
- 241000187563 Rhodococcus ruber Species 0.000 claims description 3
- 210000004520 cell wall skeleton Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- -1 tincture Substances 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 208000021145 human papilloma virus infection Diseases 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 229940008126 aerosol Drugs 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 108010073243 Nocardia cell wall skeleton Proteins 0.000 abstract 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 77
- 238000011282 treatment Methods 0.000 description 35
- 241000700605 Viruses Species 0.000 description 29
- 206010008342 Cervix carcinoma Diseases 0.000 description 25
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 25
- 201000010881 cervical cancer Diseases 0.000 description 25
- 230000009385 viral infection Effects 0.000 description 24
- 208000036142 Viral infection Diseases 0.000 description 23
- 229960005486 vaccine Drugs 0.000 description 22
- 210000003679 cervix uteri Anatomy 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 11
- 239000002981 blocking agent Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241000341655 Human papillomavirus type 16 Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 238000011238 DNA vaccination Methods 0.000 description 4
- 208000037581 Persistent Infection Diseases 0.000 description 4
- 208000019802 Sexually transmitted disease Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000004116 schwann cell Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 229940124954 vaccinia virus vaccine Drugs 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010062317 Condyloma latum Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 101150013359 E7 gene Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 102100030659 Lipase member I Human genes 0.000 description 1
- 101710102461 Lipase member I Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000003565 cervix uteri carcinoma in situ Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000022159 squamous carcinoma in situ Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 208000022625 uterine cervix carcinoma in situ Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 201000000627 variola minor Diseases 0.000 description 1
- 208000014016 variola minor infection Diseases 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
序号 | 姓名代号 | 年龄 | HPV感染型别 | 用药途径 | 治疗方法 | 次数 | 用药时间段 | 第一次月经干净3-7天 | 第二次月经干净 |
001 | WLJU | 37 | 58 | 宫颈外敷 | 隔日 | 6 | 3/8-3/18 | 阴性 | 阴性 |
002 | CHNI | 45 | CP8304 | 宫颈外敷 | 隔日 | 6 | 3/16-4/3 | CP8304 | CP8304 |
003 | ZLYI | 26 | 66 | 宫颈外敷 | 隔日 | 10 | 3/16-3/26 | 66 | 66/68 |
004 | TXYA | 46 | 56 | 宫颈外敷 | 隔日 | 6 | 3/18-3/28 | 阴性 | 阴性 |
005 | QIXU | 41 | 66 | 宫颈外敷 | 隔日 | 6 | 3/18-4/9 | 66 | 66 |
006 | WAYA | 39 | 59/6 | 宫颈外敷 | 连续 | 24 | 4/20-5/13 | 阴性 | 阴性 |
007 | LIPI | 26 | 31/33/59 | 宫颈外敷 | 连续 | 14 | 4/20-5/3 | 31/33 | 31/33 |
008 | WYME | 44 | 11/CP8304 | 宫颈外敷 | 连续 | 22 | 4/20-5/11 | CP8304 | CP8304 |
009 | XFYI | 42 | 16 | 宫颈注射 | 连续 | 20 | 7/10-8/12 | 阴性 | 阴性 |
010 | HDME | 43 | 31 | 宫颈注射 | 隔日 | 6 | 7/19-8/16 | 阴性 | 阴性 |
011 | XYLI | 26 | 31/58(CIN-I) | 宫颈注射 | 隔日 | 10 | 7/6-8/4 | 58 | 58 |
序号 | 姓名代号 | 年龄 | HPV感染型别 | 观察时间 | 第一次月经干净 | 第二次月经干净 |
101 | ZHPP | 41 | 58 | 5/7-6/16 | 58 | 58 |
102 | ZHXY | 45 | 56 | 6/1-7/5 | 56 | 56 |
103 | WALI | 30 | 11 | 6/18-7/29 | 11 | 11 |
104 | LINA | 38 | 52 | 6/6-7/15 | 52 | 52 |
105 | GLXA | 27 | 6 | 7/1-8/3 | 6 | 6 |
Claims (8)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101055337A CN1935262B (zh) | 2005-09-23 | 2005-09-23 | 红色诺卡氏菌细胞壁骨架在制备抗人乳头瘤病毒药物的用途 |
BRPI0520568A BRPI0520568B8 (pt) | 2005-09-23 | 2005-11-23 | uso de esqueleto de parede celular de nocardia rubra na preparação de medicamentos para infecção anti-hpv |
RU2008109165/15A RU2394586C2 (ru) | 2005-09-23 | 2005-11-23 | Применение скелета клеточной стенки nocardia rubra для получения лекарства против вируса папилломы человека (hpv) |
EP05811912.4A EP1938826B1 (en) | 2005-09-23 | 2005-11-23 | Use of nocardia rubra cell wall skeleton to produce medicaments for resisting human papilloma virus hpv |
PCT/CN2005/001977 WO2007033533A1 (fr) | 2005-09-23 | 2005-11-23 | Utilisation du squelette de paroi cellulaire de nocardia rubra en vue de produire des médicaments favorisant la résistance au virus du papillome humain (vph) |
KR1020087009291A KR20080048542A (ko) | 2005-09-23 | 2005-11-23 | 인간 유두종 바이러스에 저항하는 약제 제조를 위한노카르디아 루브라 세포벽 골격의 용도 |
US12/067,891 US8460722B2 (en) | 2005-09-23 | 2005-11-23 | Use of Nocardia rubra cell wall skeleton in the preparation of anti-HPV infection medicaments |
JP2008531506A JP4854742B2 (ja) | 2005-09-23 | 2005-11-23 | 抗hpv感染症薬の調製におけるノカルディア・ルブラ細胞壁骨格の使用 |
HK07108619.7A HK1100533A1 (en) | 2005-09-23 | 2007-08-08 | Use of nocardia rubra cell wall skeleton to produce medicaments for resisting human papilloma virus hpv |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101055337A CN1935262B (zh) | 2005-09-23 | 2005-09-23 | 红色诺卡氏菌细胞壁骨架在制备抗人乳头瘤病毒药物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1935262A CN1935262A (zh) | 2007-03-28 |
CN1935262B true CN1935262B (zh) | 2010-12-29 |
Family
ID=37888528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005101055337A Active CN1935262B (zh) | 2005-09-23 | 2005-09-23 | 红色诺卡氏菌细胞壁骨架在制备抗人乳头瘤病毒药物的用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8460722B2 (zh) |
EP (1) | EP1938826B1 (zh) |
JP (1) | JP4854742B2 (zh) |
KR (1) | KR20080048542A (zh) |
CN (1) | CN1935262B (zh) |
BR (1) | BRPI0520568B8 (zh) |
HK (1) | HK1100533A1 (zh) |
RU (1) | RU2394586C2 (zh) |
WO (1) | WO2007033533A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102526119A (zh) * | 2010-12-23 | 2012-07-04 | 辽宁纳可佳生物制药有限公司 | 红色诺卡氏菌细胞壁骨架增强树突状细胞功能的方法 |
CN116898881A (zh) * | 2017-01-11 | 2023-10-20 | 福建省山河药业有限公司 | 红色诺卡氏菌细胞壁骨架在制备治疗痤疮的药物/护肤品中的用途及其药物/护肤品组合物 |
CN111727235B (zh) * | 2019-01-15 | 2024-03-15 | 辽宁天安生物制药股份有限公司 | 赤红球菌产品及其制药用途 |
CN112040962A (zh) * | 2019-03-14 | 2020-12-04 | 辽宁格瑞仕特生物制药有限公司 | 红色诺卡氏菌细胞壁骨架在治疗外阴白色病变中的用途 |
US20220193148A1 (en) | 2019-04-24 | 2022-06-23 | Liaoning Greatest Bio-Pharmaceutical Co. Ltd. | Use of nocardia rubra cell wall skeleton in treatment of thermal injury |
US20230071748A1 (en) | 2020-01-21 | 2023-03-09 | Liaoning Greatest Bio-Pharmaceutical Co., Ltd. | Use of nocardia rubra cell wall skeleton in regenerative medicine |
CN115025128A (zh) * | 2022-06-24 | 2022-09-09 | 辽宁格瑞仕特生物制药有限公司 | 红色诺卡氏菌细胞壁骨架在治疗宫颈病变中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094288A (zh) * | 1993-04-23 | 1994-11-02 | 福建省微生物研究所 | 利用红色诺卡氏菌制造细胞壁骨架粉末的方法 |
CN1443542A (zh) * | 2002-03-08 | 2003-09-24 | 沈阳胜宝康生物制药有限公司 | 红色诺卡放线菌细胞壁骨架制剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5393792A (en) * | 1991-11-20 | 1995-02-28 | Advance Biofactures Of Curacao, N.V. | High dosage topical forms of collagenase |
JP4859341B2 (ja) | 2001-07-19 | 2012-01-25 | 昭 林 | ヒト免疫療法 |
AR041171A1 (es) | 2002-09-06 | 2005-05-04 | Univ London | Modulador inmune |
AU2003261624A1 (en) | 2003-09-05 | 2005-03-29 | Shenyang Sunbellcom Bio-Pharmaceutical Co., Ltd. | A red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion |
CN1879661B (zh) | 2005-06-16 | 2012-06-20 | 辽宁纳可佳生物制药有限公司 | 红色诺卡氏菌细胞壁骨架在制备抗真菌感染的药物中的用途 |
CN101073583A (zh) | 2006-05-19 | 2007-11-21 | 沈阳胜宝康生物制药有限公司 | 红色诺卡氏菌细胞壁骨架在制备药物中的用途 |
-
2005
- 2005-09-23 CN CN2005101055337A patent/CN1935262B/zh active Active
- 2005-11-23 KR KR1020087009291A patent/KR20080048542A/ko not_active Application Discontinuation
- 2005-11-23 US US12/067,891 patent/US8460722B2/en active Active
- 2005-11-23 RU RU2008109165/15A patent/RU2394586C2/ru active
- 2005-11-23 BR BRPI0520568A patent/BRPI0520568B8/pt active IP Right Grant
- 2005-11-23 WO PCT/CN2005/001977 patent/WO2007033533A1/zh active Application Filing
- 2005-11-23 EP EP05811912.4A patent/EP1938826B1/en active Active
- 2005-11-23 JP JP2008531506A patent/JP4854742B2/ja active Active
-
2007
- 2007-08-08 HK HK07108619.7A patent/HK1100533A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094288A (zh) * | 1993-04-23 | 1994-11-02 | 福建省微生物研究所 | 利用红色诺卡氏菌制造细胞壁骨架粉末的方法 |
CN1443542A (zh) * | 2002-03-08 | 2003-09-24 | 沈阳胜宝康生物制药有限公司 | 红色诺卡放线菌细胞壁骨架制剂 |
Non-Patent Citations (2)
Title |
---|
赵方辉等.宫颈癌病因学研究进展.癌症进展杂志2 1.2004,2(1),第40页左栏最后一段. |
赵方辉等.宫颈癌病因学研究进展.癌症进展杂志2 1.2004,2(1),第40页左栏最后一段. * |
Also Published As
Publication number | Publication date |
---|---|
RU2008109165A (ru) | 2009-10-27 |
US8460722B2 (en) | 2013-06-11 |
EP1938826B1 (en) | 2014-11-12 |
RU2394586C2 (ru) | 2010-07-20 |
BRPI0520568A2 (pt) | 2009-05-19 |
BRPI0520568B1 (pt) | 2019-10-08 |
CN1935262A (zh) | 2007-03-28 |
JP2009508883A (ja) | 2009-03-05 |
EP1938826A1 (en) | 2008-07-02 |
EP1938826A4 (en) | 2011-09-07 |
JP4854742B2 (ja) | 2012-01-18 |
BRPI0520568B8 (pt) | 2021-05-25 |
US20090028973A1 (en) | 2009-01-29 |
WO2007033533A1 (fr) | 2007-03-29 |
KR20080048542A (ko) | 2008-06-02 |
HK1100533A1 (en) | 2007-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1935262B (zh) | 红色诺卡氏菌细胞壁骨架在制备抗人乳头瘤病毒药物的用途 | |
Lacey et al. | Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease | |
Reid et al. | Genital warts and cervical cancer. I. Evidence of an association between subclinical papillomavirus infection and cervical malignancy | |
Carr et al. | Human papillomavirus: epidemiology, transmission, and pathogenesis | |
JP2022516984A (ja) | 単離されたロドコッカス・ルーバーの細胞壁骨格のヒトパピローマウイルス感染症を治療する医薬の製造における使用 | |
CN104353058B (zh) | 商陆抗病毒蛋白冻干粉复合剂及其制备方法 | |
US20190343870A1 (en) | Application of alginic acid sulfate in preparation of drugs and health care products for preventing and treating diseases caused by human papilloma viruses | |
US7172870B2 (en) | Treatment of papillomavirus infections | |
Burk | Human papillomavirus and the risk of cervical cancer | |
CN108815186A (zh) | 一种治疗hpv持续感染引起疾病的药物及制备方法与应用 | |
Frazer | Cervical cancer vaccine development | |
WO2024087356A1 (zh) | 间充质干细胞在制备治疗hpv持续感染的药物中的应用 | |
Androphy | Papillomaviruses and interferon | |
Al-Azmi et al. | Human papillomavirus: manifestations, prevention and treatment: an overview | |
CN100558383C (zh) | 治疗人乳头瘤病毒感染的中药 | |
Skinner et al. | Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine | |
CN110292621A (zh) | 抗hpv病毒感染的抗毒抑菌复合剂及其转相凝胶的制备方法 | |
CN1977864A (zh) | 一种预防早期宫颈Ca的新药-红色诺卡氏菌制剂及应用 | |
CN101711785A (zh) | 治疗人乳头瘤病毒感染的中药 | |
AU762114B2 (en) | Treatment of papillomavirus infections | |
Zhang et al. | Condyloma acuminatum | |
Singh et al. | Seroepidemiology of Human Papilloma Virus and HPV Vaccination in Cervical Cancer-Era of New Hope: A brief review of article | |
Roncada et al. | Prevalence of anogenital infection by Human Papillomavirus (HPV) in users of immunobiological therapy | |
Ka-Man et al. | New vaccines for prevention of HPV infection | |
Ali et al. | Cervical Cancer Care & Management: A Conquerable Malignancy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Second inventor Correct: Zhang Die False: Zhang Tie Number: 13 Volume: 23 |
|
CI02 | Correction of invention patent application |
Correction item: Second inventor Correct: Zhang Die False: Zhang Tie Number: 13 Page: The title page Volume: 23 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: THE SECOND INVENTOR; FROM: ZHANG TIE TO: ZHANG YI |
|
ERR | Gazette correction |
Free format text: CORRECT: THE SECOND INVENTOR; FROM: ZHANG TIE TO: ZHANG YI |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1100533 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: LIAONING NAKEJIA BIOLOGICAL PHARMACEUTICAL CO., LT Free format text: FORMER NAME: SHENYANG SHENGBAOKANG BIOPHARMACEUTICAL INDUSTRY CO. LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 110015, No. 7, Wen Dong Road, Dongling District, Liaoning, Shenyang Patentee after: LIAONING NAKEJIA BIOPHARMACEUTICAL Co.,Ltd. Address before: 110015, No. 7, Wen Dong Road, Dongling District, Liaoning, Shenyang Patentee before: Shenyang Sunbellcom Bio-Pharmaceutical Co.,Ltd. |
|
CI01 | Publication of corrected invention patent application |
Correction item: Inventor Correct: Zhang Ce|Zhang Yi|Hong Xiaoming|Zhang Guoying|Zhao Jian False: Zhang Ce|Zhang Yi|Hong Xiaoming|Zhang Guoying|Zhao Jian|Petri Ustaro Number: 52 Volume: 26 |
|
CI03 | Correction of invention patent |
Correction item: Inventor Correct: Zhang Ce|Zhang Yi|Hong Xiaoming|Zhang Guoying|Zhao Jian False: Zhang Ce|Zhang Yi|Hong Xiaoming|Zhang Guoying|Zhao Jian|Petri Ustaro Number: 52 Page: The title page Volume: 26 |
|
ERR | Gazette correction |
Free format text: CORRECT: INVENTOR; FROM: ZHANG CE; ZHANG YI, HONG XIAOMING, ZHANG GUOYING, ZHAO JIAN, UUSITALO PETRI TO: ZHANG CE; ZHANG YI, HONG XIAOMING, ZHANG GUOYING, ZHAO JIAN |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1100533 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: SHENYANG NUOKE BIOLOGICAL ENGINEERING CO., LTD. Free format text: FORMER OWNER: LIAONING NAKEJIA BIOLOGICAL PHARMACEUTICAL CO., LTD. Effective date: 20140312 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110015 SHENYANG, LIAONING PROVINCE TO: 110004 SHENYANG, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140312 Address after: 321 room 17-3, 110004 Wen'an Road, Heping District, Liaoning, Shenyang, China Patentee after: Shenyang Bio Technology Co.,Ltd. Address before: 110015, No. 7, Wen Dong Road, Dongling District, Liaoning, Shenyang Patentee before: LIAONING NAKEJIA BIOPHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20180413 Address after: 117004 No. 1, 1 floor, 8-2 Chun'an street, Shiqiao, Benxi, Liaoning. Patentee after: LIAONING GREATEST BIO-PHARMACEUTICAL Co.,Ltd. Address before: 321 room 17-3, 110004 Wen'an Road, Heping District, Liaoning, Shenyang, China Patentee before: Shenyang Bio Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: No.1, floor 1, building 8-2, Chun'an street, Shiqiaozi, Xihu District, Benxi City, Liaoning Province Patentee after: Liaoning Tian'an Biopharmaceutical Co.,Ltd. Address before: No.1, floor 1, building 8-2, Chun'an street, Shiqiaozi, Xihu District, Benxi City, Liaoning Province Patentee before: LIAONING GREATEST BIO-PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |